28562-68-7

Usage

Uses

Used in Organic Synthesis:
3-Oxetanecarboxylic acid, 3-methyl is used as a key intermediate in organic synthesis for the preparation of complex organic compounds. Its small and stable ring structure allows for the formation of various derivatives, making it a versatile building block in the synthesis of pharmaceuticals and other biologically active molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Oxetanecarboxylic acid, 3-methyl is utilized as a starting material for the development of new drugs and therapeutic agents. Its unique structure and functional groups enable the design and synthesis of novel compounds with potential therapeutic applications.
Used in Pharmaceutical Industry:
3-Oxetanecarboxylic acid, 3-methyl is employed in the pharmaceutical industry as a building block for the preparation of various pharmaceuticals. Its versatility and stability make it an attractive candidate for the development of new drugs with improved efficacy and selectivity.
Used in Research and Development:
Researchers in the fields of organic and medicinal chemistry study 3-Oxetanecarboxylic acid, 3-methyl to explore its unique structure and properties. This research contributes to the understanding of its potential applications and the development of new synthetic methods and strategies for the preparation of complex organic compounds and pharmaceuticals.

InChI:InChI=1/C5H8O3/c1-5(4(6)7)2-8-3-5/h2-3H2,1H3,(H,6,7)

Upstream product

• 3143-02-0 3-hydroxymethyl-3-methyloxethane 
• 7440-05-3 palladium 
• 108-10-1 4-methyl-2-pentanone 

Relevant academic research and scientific papers

MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF

Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutica

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

ANTI-MUCUS DRUGS AND USES THEREFOR

Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disord

Process for the preparation of 2,2-bis-chloro-methylalkanecarboxylic acid chlorides

A process for the preparation of a 2,2-bis-chloro-methyl-alkanecarboxylic acid of the formula STR1 in which R is hydrogen, alkyl, cycloalkyl or optionally substituted phenyl, which comprises reacting an oxetane-3-carboxylic acid of the formula STR2 or a salt thereof, with an inorganic acid chloride at a temperature between 20° C. and the boiling point of the reaction mixture. The products are known intermediates for fungicides and herbicides.